A note from Europa Press, mentions that a study of the center of the Cancer of University at Stony Brook that is published in the online edition of the journal The Lancet Oncology, stresses that the anti-cancer doubles the risk of bowel perforation. Drilling in stomach or intestines caused the death of more than 20 per cent of the study cancer patients taking the drug and was more common in those who suffered cancer advanced colorectal and kidney cancer. Bevacizumab belongs to a class of drugs called inhibitors of angiogenesis that are slowing the growth of tumors to the their blood supply cut off. The drug is beneficial in the treatment of many types of included the Colorectal, renal cell cancer, non-small cell lung cancer and the breast. The researchers, led by Shenshong Wu, conducted a meta-analysis of 17 trials involving 12.294 patients with a variety of solid tumors to assess the role of bevacizumab in gastrointestinal perforation. The authors also examined if the dose of the drug or have a specific type of cancer was related to an increased risk of developing perforation of the stomach or intestines.
The discoveries showed that the incidence of gastrointestinal perforation was of 0.9 per cent, with one two times greater risk in patients receiving the drug in comparison with controls, and a mortality rate of a 21.7 per cent in those who developed the drilling. The probability that the disorder occurs depended upon the dose of the drug. Thus, the smaller amounts of bavacizumab increased the risk of gastrointestinal perforation in 61 percent (2.5 mg/Kg per week) and the largest in a 167 percent (5 mg/Kg per week).